BEUDAMED
    FDA Adverse Event Injury Summary report: N

    UNK - CONSTRUCTS: VIPER

    MDR report key: 24835304 · Received April 9, 2026

    Report

    Report Number
    1526439-2026-00346
    Event Type
    Injury
    Date Received
    April 9, 2026
    Date of Event
    August 13, 2024
    Manufacturer
    MEDOS INTERNATIONAL SàRL CH
    Product Code
    NKB
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    PRODUCT COMPLAINT # (B)(4). THIS REPORT IS BEING SUBMITTED PURSUANT TO THE PROVISIONS OF 21 CFR, PART 803 (AND/OR PART 4, AS APPLICABLE). THIS REPORT MAY BE BASED ON INFORMATION WHICH HAS NOT BEEN INVESTIGATED OR VERIFIED PRIOR TO THE REQUIRED REPORTING DATE. THIS REPORT DOES NOT REFLECT A CONCLUSION BY DEPUY SYNTHES, OR ITS EMPLOYEES THAT THE REPORT CONSTITUTES AN ADMISSION THAT THE PRODUCT, DEPUY SYNTHES, OR ITS EMPLOYEES CAUSED OR CONTRIBUTED TO THE POTENTIAL EVENT DESCRIBED IN THIS REPORT. ADDITIONAL NARRATIVE: D4: UDI: AS THE CATALOG/MODEL NUMBER WAS NOT PROVIDED, THE (01)GTIN IS NOT AVAILABLE. IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

    Description of Event or Problem · 0

    THIS COMPLAINT IS FROM A LITERATURE SOURCE. THE FOLLOWING LITERATURE CITE HAS BEEN REVIEWED: BRODELL JD JR, LAWLOR MC, SANTANGELO G, KULP A, HADDAS R, MBAGWU C, BENN L, MESFIN A. PERCUTANEOUS LUMBOPELVIC FIXATION IS EFFECTIVE IN THE MANAGEMENT OF UNSTABLE TRANSVERSE SACRAL FRACTURES. INJURY. 2024 NOV;55(11):111825. DOI: 10.1016/J.INJURY.2024.111825. EPUB 2024 AUG 13. PMID: 39208684. OBJECTIVE/METHODS/STUDY DATA: THE PURPOSE OF THIS RETROSPECTIVE STUDY WAS TO PRESENT THE RESULTS OF A CASE SERIES OF 27 PATIENTS WHO UNDERWENT LUMBOPELVIC FIXATION PERFORMED BY A SINGLE SURGEON AT OUR ACADEMIC LEVEL ONE TRAUMA CENTER. SEVEN PATIENTS WERE MALE AND TWENTY (74 %) WERE FEMALE. 26 (96.3 %). THE AVERAGE AGE WAS 54.4 ± 25.1 YEARS. THE AVERAGE BMI WAS 23.8 ± 6.5 KG/M. ALL MINIMALLY INVASIVE PROCEDURES WERE PERFORMED USING THE DEPUY SYNTHES VIPER® SYSTEM (RAYNHAM, MA, USA). THE AVERAGE FOLLOW-UP WAS 18.7 MONTHS ± 17.6. LOT, MODEL AND CATALOG NUMBER ARE NOT AVAILABLE, BUT THE SUSPECTED DEPUY SYNTHES DEVICE POSSIBLY ASSOCIATED WITH REPORTED ADVERSE EVENTS: DEPUY SYNTHES VIPER® SYSTEM. ADVERSE EVENT(S) AND PROVIDED INTERVENTIONS POSSIBLY ASSOCIATED WITH UNK - CONSTRUCTS: VIPER (QTY 3). (N=1) PATIENT HAD SURGICAL SITE INFECTION REQUIRING A RETURN TO THE OPERATING ROOM FOR AN IRRIGATION AND DEBRIDEMENT. (N=1) PATIENT HAD DEVELOPED A DEEP VENOUS THROMBOSIS, NO INTERVENTION NOTED. (N=1) PATIENT DEVELOPED A SACRAL DECUBITUS ULCER DID NOT REQUIRE SURGICAL INTERVENTION. ADVERSE EVENT(S) AND PROVIDED INTERVENTIONS POSSIBLY ASSOCIATED WITH UNK - RODS: VIPER (QTY 2) (N=2) PATIENTS HAD ROD DISLODGMENT FROM ILIAC SCREW, NO INTERVENTION NOTED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    183534 UNK - CONSTRUCTS: VIPER THORACOLUMBOSACRAL PEDICLE SCREW SYSTEM NKB MEDOS INTERNATIONAL SàRL CH

    Patients

    Seq Age Sex Outcome Treatment
    1